Skip to main content

Advertisement

Log in

Immunohistochemical characterisation of the monoclonal antibody BLCA-38 for the detection of prostate cancer

  • Original Article
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

Background: Monoclonal antibodies (MAbs) can be used to detect, image and treat cancers. This study aimed to characterise the binding of BLCA-38 MAbs to human prostate cancer cell lines, human prostate cancer biopsy samples and normal tissues to enable future targeted studies. Methods: BLCA-38 antigen expression on cancer lines was determined by flow cytometry; that on patient specimens from normal tissues and cancers was tested by immunohistochemistry using fresh frozen tissues or paraffin-embedded tissues that had undergone antigen retrieval. Results: Cell surface BLCA-38 antigen expression was seen on DU-145, PC-3, PC-3 M and PC-3 M-MM2 prostate cancer lines, but LNCaP, MDA PCa 2a or MDA PCa 2b lines were negative. Other human lines, including 8/12 bladder cancer and A431 vulval epidermoid cells, but not breast cancer lines, expressed BLCA-38 antigen. Staining occurred in glandular epithelial cells in the majority of frozen, and paraffin-embedded prostate cancer tissues and was occasionally seen in prostatic intraepithelial neoplasia (PIN). No staining was observed in normal cadaver tissues or in benign areas from various other cancer tissues. Conclusions: The BLCA-38 antibody binds to the majority of human prostate cancers but not to normal cells, and has potential for targeting novel therapies in patients with this disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2a-h

Similar content being viewed by others

References

  1. Kohler G, Milstein G (1975) Continuous culture of fused cells secreting antibody of predefined specificity. Nature 256:495

    CAS  PubMed  Google Scholar 

  2. Walker KZ, Russell PJ, Kingsley EA, Philips J, Raghavan D (1989) Detection of malignant cells in voided urine from patients with bladder cancer, a novel monoclonal assay. J Urol 142:1578

    CAS  PubMed  Google Scholar 

  3. Bazinet M, Cote RJ, Cordon-Cardo C, Myc A, Fair WR, Old LJ (1988) Immunohistochemical characterization of two monoclonal antibodies, P25.48 and P25.91, which define a new prostate-specific antigen. Cancer Res 48:6938

    CAS  PubMed  Google Scholar 

  4. Leroy M, Teillac P, Rain JD et al (1989) Radioimmunodetection of lymph node invasion in prostatic cancer: the use of iodine-123(123I)-labeled monoclonal-prostatic acid phosphatase 227A F(ab)2 antibody fragments in vivo. Cancer (Phila) 64:1

    Google Scholar 

  5. Lopes AD, Davis WL, Rosenstraus MJ, Uveges AJ, Gilman SC (1990) Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5. Cancer Res 50:6423

    CAS  PubMed  Google Scholar 

  6. DeNardo S, Kroger LA, DeNardo G (1999) A new era for radiolabeled antibodies in cancer? Curr Opin Immunol 11:563

    Article  CAS  PubMed  Google Scholar 

  7. Palapattu GS, Reiter RE (2002) Monoclonal antibody therapy for genitourinary oncology: promise for the future. J Urol 168:2615

    PubMed  Google Scholar 

  8. Russell PJ, Hewish D, Carter T, Sterling-Levis K, Ow K, Hattarki M, Doughty L, Guthrie R, Shapira D, Molloy PL, Werkmeister JA, Kortt A (2004) Cytotoxic properties of immunoconjugates containing melittin-like peptide 101 against prostate cancer: in vitro and in vivo studies. Cancer Immunol Immunother (in press)

  9. Russell PJ, Wills EJ, Philips J, Jelbart M, Gregory P, Raghavan D (1988) Features of squamous and adenocarcinoma in the same cell in a xenografted human transitional cell carcinoma: evidence of a common histogenesis? Urol Res 16:79

    CAS  PubMed  Google Scholar 

  10. Lightfoot DV, Walker KZ, Boniface GR, Hetherington EL, Izard ME, Russell PJ (1991) Dosimetric and therapeutic studies in nude mice xenograft models with 153Samarium-labelled monoclonal antibody, BLCA-38. Antibody Immunoconjugates Radiopharm 4:319

    Google Scholar 

  11. Horoszewicz JS, Leong SS, Chiu TM, Wajsmann ZL, Friedman L, Papsidero L, Kim U, Chai LS, Sandberg AA (1980) The LNCaP cell line, a new model for studies on human prostate carcinoma. Prog Clin Biol Res 37:115

    CAS  PubMed  Google Scholar 

  12. Mickey D, Stone K, Wunderli H, Mickey G, Vollmer R, Paulson D (1977) Heterotransplantation of human prostatic adenocarcinoma cell line in nude mice. Cancer Res 37:4049

    CAS  PubMed  Google Scholar 

  13. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW (1979) Establishment and characterisation of a human prostate carcinoma cell line (PC-3). Invest Urol 17:16

    CAS  PubMed  Google Scholar 

  14. Gleave M, Hsieh J-T, Gao C, von Eschenbach AC, Chung LKW (1991) Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res 51:3753

    CAS  PubMed  Google Scholar 

  15. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL et al (1994) Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 54:2577

    CAS  PubMed  Google Scholar 

  16. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LWK (1994) Derivation of androgen-independent LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 57:406

    CAS  PubMed  Google Scholar 

  17. Pettaway CA, Pathak S, Greene G, Tamirez E, Wilson MR, Killion JJ, Fidler IJ (1996) Selection of highly metastatic variants of different human prostate carcinomas using orthotopic implantation in nude mice. Clin Cancer Res 2:1627

    CAS  PubMed  Google Scholar 

  18. Navone NM, Olive M, Ozen M, Davis R, Troncoso P, Tu SM et al (1997) Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin Cancer Res 3:2493

    CAS  PubMed  Google Scholar 

  19. Klein KA, Reiter RE, Redula J, Moradi H, Zhu XL, Brothman AR et al (1977) Progression of metastatic human prostate cancer to androgen-independence in immunodeficient SCID mice. Nat Med 3:402

    Google Scholar 

  20. Iizumi T, Yazaki T, Kanoh S, Koiso K (1987) Establishment of a new prostatic carcinoma cell line (TSU-PR-1). J Urol 137:1304

    CAS  PubMed  Google Scholar 

  21. van Bokhoven A, Varella-Garcia M, Korch C, Miller GJ (2001) TSU-Pr1 and JCA-1 cells are derivatives of T24 bladder carcinoma cells and are not of prostatic origin. Cancer Res 61:6340

    PubMed  Google Scholar 

  22. Brown JL, Russell PJ, Philips J, Wotherspoon J, Raghavan D (1990) Clonal analysis of bladder cancer cell line: an experimental model of tumour heterogeneity. Br J Cancer 61:369

    CAS  PubMed  Google Scholar 

  23. Russell PJ, Jelbart M, Wills EJ, Singh S, Wass J, Raghavan D (1988) Establishment and characterization of a new human bladder cancer cell line showing features of squamous and glandular differentiation. Int J Cancer 41:74

    CAS  PubMed  Google Scholar 

  24. Russell PJ, Wass J, Lukeis R, Garson OM, Jelbart M, Wills EJ, Philips J, Brown J, Carrington N, Vincent PC, Raghavan D (1989) Characterization of cell lines derived from a multiply aneuploid human bladder transitional-cell carcinoma, UCRU-BL-13. Int J Cancer 44:276

    CAS  PubMed  Google Scholar 

  25. O‘Toole C, Price ZH, Ohnuki Y, Unsgaard B (1978) Ultrastructure, karyology and immunology of a cell line orinated from a transitional cell carcinoma. Br J Cancer 38:64

    CAS  PubMed  Google Scholar 

  26. Bubenik J, Perlman P, Helmstein K, Moberger G (1970) Cellular and humoral immune responses to human urinary bladder carcinomas. Int J Cancer 5:310

    CAS  PubMed  Google Scholar 

  27. Zinzar SN, Svet Moldavsky GJ, Fogh J, Mann PE, Arlin Z, Ilescu K, Holland JF (1985) Elaboration of granulocyte-macrophage colony stimulating factor by human tumor cell lines and normal urothelium. Exp Hematol 13:574

    CAS  PubMed  Google Scholar 

  28. Lundy EG, Sorokin CF, Meltz SK, Glade PR (1977) Reversible inhibition of human peripheral lymphocyte DNA synthesis by an extract of breast cancer cell line SKBR3. J Surg Res 22:654

    Article  CAS  PubMed  Google Scholar 

  29. Koga M, Musgrove EA, Sutherland RL (1990) Differential effects of phorbol ester on epidermal growth factor receptors in estrogen receptor-positive and -negative breast cancer cell lines. Cancer Res 50:4849

    CAS  PubMed  Google Scholar 

  30. Rizk NN (1982) Scanning electron microscopic study of three human breast cancer cell lines. Acta Cytol 26:714

    CAS  PubMed  Google Scholar 

  31. Haigler H, Ash JF, Singer SJ, Cohen S (1978) Visualization by fluorescence of the binding and internalization of epidermal gowth factor in human carcinoma cells. Proc Natl Acad Sci U S A 75:3317

    CAS  PubMed  Google Scholar 

  32. Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell D, Raymond R, Stables J, Stephens T, Wallace J (1998) United Kingdom coordinating committee guidelines for the welfare of animals in experimental neoplasia, 2nd edn. Br J Cancer 77:1

    Google Scholar 

  33. Walker KZ, Seymour-Munn K, Keech FK, Axiak SM, Bautovich GH, Morris JC, Basten A (1986) A rat model system for radioimmunodetection of kappa myeloma antigen on malignant B cells. Eur J Nucl Med 12:461

    CAS  PubMed  Google Scholar 

  34. Li Y, Tian Z, Rizvi SMA, Bander NH, Allen BJ (2002) In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen. Prostate Cancer Prostatic Dis 5:36

    CAS  PubMed  Google Scholar 

  35. Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S, Pulford KA, Stein H, Mason DY (1984) Immunoenzymatic labeling of monoclonal antibodies using immune complexs of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 32:219

    CAS  PubMed  Google Scholar 

  36. Ow KT, Mameghan H, Lochhead A, Fisher R, Yang J-L, Mameghan J, Andersen S, Russell PJ (1995) The prognostic significance of tumor-associated markers p53, HER-2/neu, c-myc, v-H-ras, PCNA and EGFr of local and distant recurrence in localised human prostatic adenocarcinoma. Urol Oncol 1:144

    Article  Google Scholar 

  37. Todorovska A, Roovers RC, Dolezal O, Kortt AA, Hoogenboom HR, Hudson J (2001) Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J Immunol Methods 248:47

    Article  CAS  PubMed  Google Scholar 

  38. Fossa A, Alsoe L, Crameri R, Funderud S, Gaudernack G, Smeland EB (2004) Serological cloning of cancer/testis antigens expressed in prostate cancer using cDNA phage surface display. Cancer Immunol Immunother (in press)

  39. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, Knudsen B, Bander NH (1997) Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 57:3629

    CAS  PubMed  Google Scholar 

  40. Trabulsi EJ, Yao D, Joyce MA, Milowksy M, Kostakoglu L, Vallabhajosula D Nanus D, Goldsmith S, Bander NH (2003) Phase I radioimmunotherapy (RIT) trials of monoclonal antibody (MAB) J591 to the extracellular domain of prostate specific membrane antigen (PSMAEXT) radiolabeled with yttrium 90 (90Y) or lutetium 177 (177Lu). J Urol 169[Suppl 4]

  41. Trabulsi EJ, Yao D, Kostakoglu L, Vallabhajosula S, Hoyce MA, Milowksy M, Nanus DM, Goldsmith SJ, Bander NH (2003) Targeting metastatic prostate cancer with radiolabeled J591 monoclonal antibody (MAB) specific for the extracellular domain of prostate specific membrane antigen. J Urol 169[Suppl 4]

  42. Ware JL, Paulson DF, Parks SF, Webb KS (1982) Production of monoclonal antibody alpha Pro3 recognizing a human prostatic carcinoma antigen. Cancer Res 42:1215

    CAS  PubMed  Google Scholar 

  43. Starling JJ, Wright GL Jr (1985) Disulfide bonding of a human tumor-associated membrane antigen recognized by monoclonal antibody D83.21. Cancer Res 45:804

    CAS  PubMed  Google Scholar 

  44. Lipford GB, Wright GL Jr (1991) Comparative study of monoclonal antibodies TURP-27 and HNK-1: their relationship to neural cell adhesion molecules and prostate tumor-associated antigens. Cancer Res 51:2296

    CAS  PubMed  Google Scholar 

  45. Kingsley EA, Russell PJ (1999) Radioimmunotherapy of superficial bladder cancer. In: Riva P (ed) Therapy of malignancies with radioconjugated monoclonal antibodies: present possibilities and future prospectives. Harwood Academic Publishers, The Netherlands, pp 411–441

  46. Li Y, Rivzi SMA, Blair JM (nee Brown), Cozzi PJ, Qu CF, Ow KT, Tam PN, Perkins AC, Russell PJ, Allen BJ (2004) Antigenic expression of human metastatic prostate cancer cell lines for in vitro multiple-targeted α-therapy with 213Bi-conjugates. Int J Radiation Oncology Biol Phys 59: in press

    Google Scholar 

  47. He XY, Xu Z, Melrose J, Mullowney A, Vasquez M, Queen C, Vexler V, Klingbeil C, Co MS, Berg EL (1998) Humanization and pharmacokinetics of a monoclonal antibody with specificity for both E- and P-selectin. J Immunol 160:1029

    CAS  PubMed  Google Scholar 

  48. Carter T, Sterling Levis K, Ow K, Doughty L, Hattarki M, Shapira D, Hewish D, Kortt AA, Russell PJ (2004) Biodistributions of intact monoclonal antibodies and fragments of BLCA-38, a new prostate cancer directed antibody. Cancer Immunol Immunother 53:533

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We wish to thank the pathologists, Prof. Christer Busch (University of Tromso, Tromso, Norway), Drs Alistair Lochhead (Sutherland Pathology, Wollongong, NSW, Australia), John Pedersen (Melbourne Pathology, Victoria, Australia) and Warick Delprado (Douglass Hanly Moir, Sydney, Australia) for providing human specimens suitable for study, and Dr Angus Collins (Douglass Hanly Moir, Sydney, Australia) for help with interpretation of Gleason scores in the prostate cancer biopsy samples. We also wish to thank the above-mentioned pathologists and Dr Elin Mortensen (University of Tromso, Tromso, Norway) for help with reading the intensity of some BLCA-38 staining in our laboratory.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to P. J. Russell.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Russell, P.J., Ow, K.T., Tam, P.N. et al. Immunohistochemical characterisation of the monoclonal antibody BLCA-38 for the detection of prostate cancer. Cancer Immunol Immunother 53, 995–1004 (2004). https://doi.org/10.1007/s00262-004-0527-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-004-0527-7

Keywords

Navigation